Through the elevated levels of CD4+ T cells previously found in BRAF-mutant tumor samples, the BRAF-mutant TME can promote anti-tumor activity through the direct or indirect targeting of tumor cells by CD4+ T cells, which also supports the cytotoxic effects of CD8 + T cells on tumor cells [62,64]. Here, CD8A is linked to neoplasm.